Hemochromatosis

Foreword; Part I. Introduction to Hemochromatosis: 1. A brief history of hemochromatosis; 2. Hemochromatosis: a genetic definition; Part II. Genetics of Hemochromatosis: 3. Inheritance of hemochromatosis: family studies; 4. Hemochromatosis: population genetics; 5. Variation of hemochromatosis prevalence and genotype in national groups; 6. Human leukocyte antigen (HLA) association and typing in hemochromatosis; 7. Localisation, allelic heterogeneity, and origins of the hemochromatosis gene; 8. The ancestral haplotype in hemochromatosis; 9. Evidence for multiple hemochromatosis genes; Part III. Metal Absorption and Metabolism in Hemochromatosis: 10. Intestinal iron-binding proteins; 11. Intestinal iron absorption and hemochromatosis; 12. The absorption and metabolism of non-ferrous metals in hemochromatosis; 13. Ferritin metabolism in hemochromatosis; 14. Hepatic iron metabolism in hemochromatosis; 15. Extra-hepatic iron metabolism in hemochromatosis; 16. Mathematical models of metal metabolism in hemochromatosis; 17. Expression of iron overload in hemochromatosis; Part IV. Diagnostic Techniques for Iron Overload: 18. Liver biopsy in hemochromatosis; 19. Histochemistry of iron and iron-associated proteins in hemochromatosis; 20. Computed tomography and magnetic resonance imaging in the diagnosis of hemochromatosis; Part V. Complications of Iron Overload: 21. Mechanisms of iron toxicity; 22. Iron as a carcinogen; 23. Clinical spectrum of hepatic disease in hemochromatosis; 24. The arthropathy of hemochromatosis; 25. Diabetes mellitus and hemochromatosis; 26. Non-diabetic endocrinopathy in hemochromatosis; 27. Cutaneous manifestations of hemochromatosis; 28. Cardiac abnormalities in hemochromatosis; 29. Estimate of the frequency of morbid complications of hemochromatosis; 30. Juvenile hemochromatosis; Part VI. Therapy of Hemochromatosis and Iron Overload: 31. Management of hemochromatosis; 32. Chelation therapy in iron overload; 33. Liver transplantation and hemochromatosis; 34. Survival in hemochromatosis; Part VII. Infections and Immunity in Hemochromatosis: 35. Role of iron in infections and immunity; 36. Bacterial infections in hemochromatosis; 37. Chronic viral hepatitis and hemochromatosis; 38. T-lymphocyte expression and function in hemochromatosis; Part VIII. Hemochromatosis Heterozygotes: 39. The iron phenotype of hemochromatosis heterozygotes; 40. Ascertainment of hemochromatosis heterozygosity; 41. Disease risk in hereditary hemochromatosis heterozygotes; Part IX. Relationship of Hemochromatosis to Other Disorders: 42. Thalassemias and their interactions with hemochromatosis; 43. Iron overload in sideroblastic and other non-thalassemic anemias; 44. Hemochromatosis, iron overload, and porphyria cutanea tarda; 45. Interactions of alcohol, iron, and hemochromatosis; 46. Iron overload in African Americans; Part X. Animal Models of Hemochromatosis and Iron Overload: 47. Beta-2 microglobulin-deficient mice as a model for hemochromatosis; 48. Animal models of iron overload based on excess exogenous iron; 49. Naturally occurring iron overload in animals; Part XI. Screening for Hemochromatosis: 50. Screening tests for hemochromatosis; 51. Cost-effectiveness of screening for hemochromatosis; Part XII. Hemochromatosis: Societal and Ethical Issues: 52. Hemochromatosis: effect of iron fortification of foods; 53. Iron overload, public health and genetics: evaluating the evidence for hemochromatosis screening; 54. Ethical issues and hemochromatosis; 55. Hemochromatosis patients as blood and tissue donors; 56. Genetic counseling for hemochromatosis; Part XIII. Final Issues: 57. Problems to be solved and directions for future investigations.